deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT04195906

Phase 3 Study of SNF472 for Calciphylaxis (Calciphyx)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis

Sponsor: Sanifit Therapeutics S. A.

Updated 21 times since 2020 Last updated: Jan 25, 2024 Started: Feb 12, 2020 Primary completion: Oct 24, 2022 Completion: Oct 24, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Calcific Uremic Arteriolopathy and Calciphylaxis, this trial is completed. The trial is conducted by Sanifit Therapeutics S. A. and has accumulated 21 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Mar 2024 · 18 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  5. Sep 2022 — Mar 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

Show 16 earlier versions
  1. Dec 2021 — Sep 2022 [monthly]

    Recruiting PHASE3

  2. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  3. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  4. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  5. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  6. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  9. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  10. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  11. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  12. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  13. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  14. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  15. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  16. Jan 2020 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanifit Therapeutics S. A.
Data source: Sanifit Therapeutics S. A.

For direct contact, visit the study record on ClinicalTrials.gov .